Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Womens Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2020 after the market closes on Thursday, August 6, 2020, and will host a conference call at 5:30 pm ET that day to discuss those results.


GlobeNewswire Inc | Jul 23, 2020 08:00AM EDT

July 23, 2020

NEW YORK, July 23, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA), a medical technology company focused on Womens Health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended June 30, 2020 after the market closes on Thursday, August 6, 2020, and will host a conference call at 5:30 pm ET that day to discuss those results.

To participate in the conference call, dial (877) 376-9925 (U.S. and Canada) or (629) 228-0732 (International) and use conference ID number 2649347. The call will also be available via live or archived webcast on the Investor Relations section of the Establishment Labs website atwww.establishmentlabs.com.

About Establishment Labs Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on womens health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants, the centerpiece of the MotivaImagineplatform. Motiva Implantsare produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Companys direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implantclinical trial in the United States in April 2018. In addition to Motiva Implants, Establishment Labs product and technologies portfolio includes the Divina3D Simulation System and other products and services. Please visit our website for additional information:www.establishmentlabs.com

Investor/Media Contact:David K. EricksonEstablishment Labs Holdings Inc.949-447-6671derickson@establishmentlabs.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC